Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic ...
Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic lymphocytic leukemia (CLL) and mantle Cell lymphoma (MCL). Treat and ...
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) ...
Hosted on MSN
Time-Limited or Indefinite Therapy in CLL
Both time-limited therapy and continuous therapy for chronic lymphocytic leukemia (CLL) have potential benefits and drawbacks. The best choice, a joint decision between clinician and patient, should ...
In the age of targeted therapy, what’s the best long-term strategy to treat chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries? Should treatment be continuous to achieve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback